Expression patterns of miRNA-184 and miRNA-483 in cumulus granulosa cells and serum in infertile women with polycystic ovary syndrome undergoing in vitro fertilization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210522001

Enrollment

Registered

2021-05-22

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Expression patterns of miRNA-184 and miRNA-483 in cumulus granulosa cells and serum in infertile women with polycystic ovary syndrome undergoing in vitro fertilization Cumulus granulosa cell, In vitro fertilization, miRNA, Polycystic ovary syndrome, Serum

Interventions

Infertile women diagnosed with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization at Infertility Clinic, King Chulalongkorn Memorial Hospital,Non-PCOS women undergoing in vitro fertili

Diagnostic,Diagnostic

PCOS,Control

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: PCOS group 1. Age 18-45 years old 2. Diagnosed with PCOS by 2003 ESHRE/ASRM Revised Rotterdam consensus criteria including at least 2 out of 3 of these manifestations 2.1 Oligo-anovulation 2.2 Clinical and/or biochemical signs of hyperandrogenism 2.3 Ultrasonographic evidence of polycystic ovary defining as presentation of more than 12 follicles size ranging from 2-9 mm or ovarian volume exceeds 10 mL3 in at least one ovary (Polycystic ovarian morphology; PCOM) 3. Undergoing IVF for infertility treatment Control group 1. Age 18-45 years old 2. Defined as normal responder to ovarian stimulation (total number of oocytes retrieved after completion of ovarian stimulation ranges from 5-15 oocytes) 3. Regular menstrual cycle with interval ranges from 21 to 35 days 4. No clinical sign of hyperandrogenism (acne, hirsutism (Modified Ferriman-Gallwey score exceeds 3 in Thai women(28)), androgenic alopecia) 5. No ultrasonographic evidence of PCOM

Exclusion criteria

Exclusion criteria: 1. Gynecologic cancer 2. Endometriosis by clinical diagnosis, suggestive physical examination, imaging evidence or confirmed diagnosis in operation 3. Systemic endocrinologic diseases (Cushing syndrome, congenital adrenal hyperplasia, thyroid carcinoma, pituitary adenoma)

Design outcomes

Primary

Measure	Time frame
Cumulus granulosa cell miRNA-184 and miRNA-483 expression after ovarian stimulation qPCR	—

Secondary

Measure	Time frame
Serum granulosa cell miRNA-184 and miRNA-483 expression after ovarian stimulation qPCR	—

Countries

Thailand

Contacts

Public ContactPorntip Sirayapiwat

Chulalongkorn University

p_siraya@hotmail.com022564241

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026